amino acid substitution comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Patients being treated for osteoporosis or non-malignant bone disease with oral bisphosphonates/quarterly or yearly infusions of intravenous bisphosphonates for >5 years Patients being treated for osteoporosis or non-malignant bone disease with bisphosphonates/denosumab for any length of time as well as being treated with systemic glucocorticoids Patients being treated with anti-resorptive/anti-angiogenic drugs/both as part of cancer management Previous MRONJ diagnosis "N.B. Patients who have taken bisphosphonate drugs at any time in the past and those who have taken denosumab in the last nine months are allocated to a risk group as if they are still taking the drug."
==== Transport proteins and membrane translocons ==== After a chloroplast polypeptide is synthesized on a ribosome in the cytosol, an enzyme specific to chloroplast proteins phosphorylates, or adds a phosphate group to many (but not all) of them in their transit sequences. Phosphorylation helps many proteins bind the polypeptide, keeping it from folding prematurely. This is important because it prevents chloroplast proteins from assuming their active form and carrying out their chloroplast functions in the wrong place—the cytosol. At the same time, they have to keep just enough shape so that they can be recognized by the chloroplast. These proteins also help the polypeptide get imported into the chloroplast. From here, chloroplast proteins bound for the stroma must pass through two protein complexes—the TOC complex, or translocon on the outer chloroplast membrane, and the TIC translocon, or translocon on the inner chloroplast membrane translocon. Chloroplast polypeptide chains probably often travel through the two complexes at the same time, but the TIC complex can also retrieve preproteins lost in the intermembrane space.
The first reference in the literature to a commercially available protein A chromatography resin appeared in 1976. Today, chromatographic separation using protein A immobilized on porous substrates is the most widely established method for purifying monoclonal antibodies (mAbs) from harvest cell culture supernatant. The choice of protein A as the preferred method is due to the high purity and yield which are easily and reliably achieved. This forms the basis for a general antibody purification "platform" which simplifies manufacturing operations and reduces the time and effort required to develop purification processes. A typical mAb purification process is shown at right. Albeit the long history of protein A chromatography for the production of antibodies, the process is still being improved today. Continuous chromatography, more precisely periodic counter-current chromatography, enormously increases the productivity of the purification step.
== Advantages == Ionization of the substrate is very efficient as it occurs at atmospheric pressure, and thus has a high collision frequency. Additionally, APCI considerably reduces the thermal decomposition of the analyte because of the rapid desolvation and vaporization of the droplets in the initial stages of the ionization. This combination of factors most typically results in the production of ions of the molecular species with fewer fragmentations than many other ionization methods, making it a soft ionization method. Another advantage to using APCI over other ionization methods is that it allows for the high flow rates typical of standard bore HPLC (0.2–2.0 mL/min) to be used directly, often without diverting the larger fraction of volume to waste. Additionally, APCI can often be performed in a modified ESI source. The ionization occurs in the gas phase, unlike ESI, where the ionization occurs in the liquid phase. A potential advantage of APCI is that it is possible to use a nonpolar solvent as a mobile phase solution, instead of a polar solvent, because the solvent and molecules of interest are converted to a gaseous state before reaching the corona discharge needle. Because APCI involves a gas-phase chemistry, there is no need to use special conditions such as solvents, conductivity, pH for LC. APCI appears to be more versatile LC/MS interface and more compatible with reversed-phase LC than ESI.
Sources: en.wikipedia.org
=== Applied Radiation Corporation === In June 1960, High Voltage Engineering Corporation acquired Applied Radiation Corporation (ARCO) of Walnut Creek, California through a stock exchange. ARCO manufactured a line of linear accelerators with uses complementing those of HVEC's existing Van de Graaff accelerators. Applied Radiation was established as a separate subsidiary under its existing management, though its sales operations were integrated with HVEC's broader organization. The acquisition, however, would prove short-lived due to antitrust concerns. At the time, HVEC dominated the market for research accelerators, controlling an 80 percent share of orders. In April 1963, the Federal Trade Commission issued a consent decree requiring HVEC to divest itself of Applied Radiation Corporation. This forced divestiture reflected FTC concerns about concentration in the particle accelerator manufacturing industry, as both firms competed for research and industrial accelerator clients.
=== Early life === McKinty was born in Belfast, Northern Ireland in 1968. The fourth of five children, he grew up in the Victoria area of Carrickfergus, County Antrim. His father was a welder and boilermaker at the Harland and Wolff shipyard before becoming a merchant seaman. He grew up reading science fiction and crime novels by the likes of Ursula Le Guin, J G Ballard and Jim Thompson. He studied law at the University of Warwick and politics and philosophy at the University of Oxford. After graduating from Oxford in 1993, McKinty moved to New York and found work in a number of occupations: security guard, barman, bookstore clerk, rugby coach, door to door salesman and librarian for the Columbia University Library. In 1999, while his wife studied for a Fulbright in Israel, McKinty played loose head prop forward for the Jerusalem Lions Rugby Club. In 2000, he relocated to Denver, Colorado, to become a high school English teacher.
=== Haddie Braverman === Haddie Braverman (Sarah Ramos) is Adam and Kristina's oldest child. She is 15 in the beginning of the series. She is a straight-A student who plays soccer and has several friends; she aspires to be the quintessential "good girl" to compensate for her brother's behavioral problems. As the show progresses, however, she begins to assert her independence and experiment with boys and drugs. In Season 2, she volunteers in a soup kitchen where she meets Alex. They become romantically involved, but her parents object to their relationship because they feel Alex is too mature for her, with too many "grown-up" problems (he is a recovering alcoholic who left an abusive home and lives alone). Her parents' opposition to their relationship, as well as removing her right to privacy, causes Haddie to move out to live with her grandparents. The conflict is eventually resolved when Haddie returns home, and Adam and Kristina grant her permission to continue seeing her boyfriend. She loses her virginity to Alex the night of her junior prom. On another occasion, her parents find out she is having sex when she misdials them during sex. During the beginning of the third season, Alex gets arrested and charged with assault after punching another man at a party. Haddie feels personally responsible since he was only there to pick her up. Alex soon ends the relationship with her even after the charges are dropped because he feels that they are too different. She dedicates the rest of her senior year to school, and gets accepted into Cornell.
== External links == Skin graft. MedlinePlus Medical Encyclopedia. Parts of this US Federal Government public domain text were used in the article. An introduction to the use of vacuum assisted closure.
=== NAADP activators === NAADP is charged and cannot cross cell membranes. Therefore, an inactive, lipophilic ester precursor (NAADP/AM) has been synthesised which crosses membranes and rapidly regenerates NAADP in the cytosol following the action of endogenous esterases. Caged NAADP is an inactive, membrane-impermeant analog of NAADP that can be introduced into cells by microinjection or a patch pipette. Flash photolysis with a UV light source rapidly converts this into NAADP, allowing the experimenter to precisely manipulate NAADP levels in time and space.
Sources: en.wikipedia.org
=== India === In India, the number of individuals affected by osteoarthritis has increased from 23.46 million in 1990 to 62.35 million in 2019. Knee osteoarthritis was the most prevalent type of osteoarthritis, followed by hand osteoarthritis. In 2019, osteoarthritis was the 20th most common cause of years lived with disability (YLDs) in India, accounting for 1.48% of all YLDs, which increased from 1.25% and 23rd most common cause in 1990.
=== Hybrid === When the parent anticyclone is weaker or not ideally located, the diabatic process must start to contribute in order to develop CAD. In scenarios where there is an equal contribution from dry synoptic forcing and diabatic processes, it is considered a hybrid damming event. The 250-mb jet is weaker and slightly farther south relative to a classical composite 24 hours prior to CAD onset. With the surface parent high farther west, it builds in eastward into the northern Great Plains and western Great Lakes region, located beneath a region of confluent flow from the 250-mb jet.
Once activated, dendritic cells migrate to lymph nodes, where they present the antigen to T cells and B cells. This triggers the production of antibodies specifically targeted to the antigen, ultimately resulting in immunity.
== History == The use of drugs in sports goes back centuries, about back to the very invention of the concept of sports. In ancient times, when the fittest of a nation were selected as athletes or combatants, they were fed diets and given treatments considered beneficial to help increase muscle. For instance, Scandinavian mythology says Berserkers could drink a mixture called "butotens" to greatly improve their physical power at the risk of insanity, which is thought to have been prepared using the Amanita muscaria mushroom. The ancient Olympics in Greece have been alleged to have had forms of doping. In ancient Rome, where chariot racing had become a huge part of their culture, athletes drank herbal infusions to strengthen them before chariot races. From that moment, people started to introduce their specific diets to improve their performance. Lots of athletes were mainly focusing on achieving superiority and winning the competition by increasing muscle strength capacity and endurance. Charmis, the Spartan winner of the Stade race in the Olympic Games of 668 BC, introduced the special diet of consuming enough dried figs during the training period. A participant in an endurance walking race in Britain, Abraham Wood, said in 1807 that he had used laudanum (which contains opiates) to keep him awake for 24 hours while competing against Robert Barclay Allardyce. By April 1877, walking races had stretched to 800 kilometres (500 mi) and the following year, also at the Agricultural Hall in Islington, London, to 840 kilometres (520 mi). The Illustrated London News chided:
=== Divisions and global locations === Ajinomoto currently operates separate divisions for North America, Latin America, and Asia, with Europe, the Middle East, and Africa being combined into the EMEA division. Ajinomoto also owns dozens of subsidiaries globally for its food, biochemical, and healthcare businesses.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.